



## **JPMorgan Annual Healthcare Conference to Webcast Alkermes' Corporate Presentation**

January 2, 2007

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 2, 2007--Alkermes, Inc. (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live by JPMorgan on Wednesday, January 10, 2007 at 11:30 a.m. EST (8:30 a.m. PST). Richard Pops, CEO of Alkermes, will provide an overview of the Company and review the Company's corporate goals for 2007. The presentation will be webcast from the Westin St. Francis Hotel in San Francisco, California and may be accessed under the investor relation's tab at [www.alkermes.com](http://www.alkermes.com). The presentation will be archived for 30 days.

Alkermes, Inc. is a biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Alkermes currently has two commercial products: RISPERDAL(R) CONSTA(R) ((risperidone) long-acting injection), the first and only long-acting atypical antipsychotic medication approved for use in schizophrenia, and marketed worldwide by Janssen-Cilag (Janssen), a wholly owned division of Johnson & Johnson; and VIVITROL(R) (naltrexone for extended-release injectable suspension) the first and only once-monthly injectable medication approved for the treatment of alcohol dependence and marketed in the U.S. primarily by Cephalon, Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes. Alkermes' headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

VIVITROL(R) is a registered trademark of Cephalon, Inc. and RISPERDAL(R) CONSTA(R) is a registered trademark of Johnson & Johnson Corporation.

CONTACT: Alkermes, Inc. Sara Brown, 617-583-6166 Senior Associate, Corporate Communications SOURCE: Alkermes, Inc.